Brief: Can-Fite Reports Progress In The Development Of Piclidenoson For Osteoarthritis In Pets Through Its Partner Vetbiolix
17/08/2022 12:34
Aug 17 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE: REPORTS PROGRESS IN THE DEVELOPMENT OF
PICLIDENOSON
FOR OSTEOARTHRITIS IN PETS THROUGH ITS PARTNER VETBIOLIX
* CAN FITE BIOPHARMA LTD - SAFETY STUDY SUCCESSFULLY
COMPLETED;
EFFICACY TRIAL TO COMMENCE AND FINANCIALLY COVERED BY VETBIOLIX
Source text for Eikon: ID:nBw5BPNnha
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage